{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Therapy+for+head+and+neck+cancer&page=10", "query": { "intervention": "Therapy for head and neck cancer", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 790, "total_pages": 79, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Therapy+for+head+and+neck+cancer&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Therapy+for+head+and+neck+cancer&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T02:20:58.480Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05307939", "title": "A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV", "Oropharynx Cancer", "HPV-Related Carcinoma", "HPV-Related Malignancy", "HPV Positive Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "HPV ctDNA Assay", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Studies", "type": "DIAGNOSTIC_TEST" }, { "name": "EORTC QLQ H&N 35 and C30", "type": "BEHAVIORAL" }, { "name": "MDADI-HN", "type": "BEHAVIORAL" }, { "name": "COST-FACIT", "type": "BEHAVIORAL" }, { "name": "Intensity-Modulated Radiation Therapy (Arm A)", "type": "RADIATION" }, { "name": "Chemoradiation (Arm B)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "BEHAVIORAL", "RADIATION", "COMBINATION_PRODUCT" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-03-24", "completion_date": "2027-03-24", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-15T02:20:58.480Z", "location_count": 8, "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05307939" }, { "nct_id": "NCT00756951", "title": "Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oral Mucositis", "Head and Neck Cancer" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "SCV-07", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciClone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2008-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-11-23", "last_synced_at": "2026-10-15T02:20:58.480Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00756951" }, { "nct_id": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non-Small Cell Lung Cancer", "Head and Neck Cancer", "Melanoma", "Gastric Cancer", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Resectable Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "INBRX-106 - Hexavalent OX40 agonist antibody", "type": "DRUG" }, { "name": "pembrolizumab 200 mg", "type": "DRUG" }, { "name": "pembrolizumab 400 mg", "type": "DRUG" }, { "name": "Carboplatin AUC-5", "type": "DRUG" }, { "name": "Carboplatin AUC-6", "type": "DRUG" }, { "name": "Pemetrexed 500 mg/m2", "type": "DRUG" }, { "name": "Cisplatin 75mg/m2", "type": "DRUG" }, { "name": "Paclitaxel 200mg/m2", "type": "DRUG" }, { "name": "Nab paclitaxel 100mg/m2", "type": "DRUG" }, { "name": "Gemcitabine (1000 mg/m2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2019-12-10", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-15T02:20:58.480Z", "location_count": 30, "location_summary": "Duarte, California • Glendale, California • Los Angeles, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04198766" }, { "nct_id": "NCT06710756", "title": "Lead-212 PSV359 Therapy for Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Esophageal Cancer", "Colorectal Cancer", "Ovarian Cancer", "Head and Neck Cancer", "Sarcoma", "Mesothelioma" ], "interventions": [ { "name": "[203Pb]Pb-PSV359", "type": "DRUG" }, { "name": "[212Pb]Pb-PSV359", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Perspective Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 112, "start_date": "2025-04-28", "completion_date": "2032-05-28", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-15T02:20:58.480Z", "location_count": 16, "location_summary": "Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06710756" }, { "nct_id": "NCT04892173", "title": "JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Squamous Cell" ], "interventions": [ { "name": "JNJ-90301900 (NBTXR3)", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Johnson & Johnson Enterprise Innovation Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 500, "start_date": "2021-12-10", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-15T02:20:58.480Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04892173" }, { "nct_id": "NCT05338905", "title": "Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Palliative Therapy", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-10-11", "completion_date": "2027-12-17", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-15T02:20:58.480Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05338905" }, { "nct_id": "NCT00003139", "title": "Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer", "Oral Complications" ], "interventions": [ { "name": "pilocarpine hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 249, "start_date": "1998-03", "completion_date": "2002-10", "has_results": false, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-10-15T02:20:58.480Z", "location_count": 216, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003139" }, { "nct_id": "NCT04555837", "title": "Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2020-09-15", "completion_date": "2025-04-08", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-10-15T02:20:58.480Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04555837" }, { "nct_id": "NCT03612531", "title": "Manual Therapy in Treating Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer Survivor", "Dysphagia", "Fibrosis", "Head and Neck Carcinoma" ], "interventions": [ { "name": "Manual Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2018-08-06", "completion_date": "2028-12-31", "has_results": true, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T02:20:58.480Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03612531" }, { "nct_id": "NCT03686124", "title": "ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Cancer", "Recurrent Cancer", "Solid Tumor, Adult", "Cancer" ], "interventions": [ { "name": "IMA203 Product", "type": "BIOLOGICAL" }, { "name": "IMA203 product- flat dose", "type": "BIOLOGICAL" }, { "name": "IMA203CD8 Product", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "IMADetect®", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Immatics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 375, "start_date": "2019-05-14", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-15T02:20:58.480Z", "location_count": 13, "location_summary": "Stanford, California • Aurora, Colorado • Miami, Florida + 8 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03686124" } ] }